QA: BIOMARIN PHARMACEUTICAL INC in us_pharma/2016

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001048477_2017_BIOMARIN_PHARMACEUTICAL_INC.pdf

Logs

warning Large missing amount for aggregate "Revenues" added to remainder. industry.us_generic {'missing_ratio': 2.0, 'aggregate_val': -1116854000, 'exp_sum': 1116854000, 'exp_to_value': {'remainder_Revenues': 1116854000}}
warning Large missing amount for aggregate "Expenses" added to remainder. industry.us_generic {'missing_ratio': 2.630510148141688, 'aggregate_val': 2331107000, 'exp_sum': 642088000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 209620000, 'SellingGeneralAndAdministrativeExpense': 476593000, 'ResearchAndDevelopmentExpense': 661905000, 'remainder_Expenses': -706030000}}
warning Expenses in unusual place in relation to revenue input.sec.calculation_linkbase.edgar_model_mapping {'expenses_node': 'CostsAndExpenses', 'revenue_node': 'Revenues', 'net_inc_node': 'NetIncomeLoss'}
info Added remainder_ComprehensiveNetIncome directly from 10K industry.us_generic {}

Graph

Absolute values for 0001048477, BIOMARIN PHARMACEUTICAL INC

  xvar xval
0 AssetsCurrent 1,421,791,000
1 IntangibleAssetsNetIncludingGoodwill 750,819,000
2 PropertyPlantAndEquipmentNet 798,768,000
3 remainder_Assets 1,052,312,000
4 LiabilitiesCurrent 439,310,000
5 LiabilitiesNoncurrent 42,034,000
6 remainder_Liabilities 776,071,000
7 CostOfGoodsAndServicesSold 209,620,000
8 SellingGeneralAndAdministrativeExpense 476,593,000
9 ResearchAndDevelopmentExpense 661,905,000
10 remainder_Expenses 982,989,000
11 remainder_Revenues -1,116,854,000
12 remainder_NetIncome 11,878,000
13 remainder_ComprehensiveNetIncome -8,217,000
  yvar yval
0 Assets 4,023,690,000
1 Liabilities 1,257,415,000
2 Expenses 2,331,107,000
3 Revenues -1,116,854,000
4 StockholdersEquity 2,766,275,000
5 NetIncome -3,436,083,000
6 ComprehensiveNetIncome -3,440,191,500
7 BaseVar 4,374,580,500
8 EconomicCapitalRatio 0.499

Edgar->Model Mapping

Feature Distribution